AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05304000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Box Breathing
Description: Participants are informed they should sit down in a chair or lie down, and to get a timer. Then they are told to take the CO2 tolerance test as follows: Take 4 breaths through the nose. Then take a maximally deep breath and once your lungs are full, exhale as slowly as possible through your nose or mouth. Time how long it takes to empty your lungs; this will be your C02 discard duration. Use your discard duration to determine how long your inhales, exhales, and breath holds should be (CO2 discard time) by using this table: \<20 sec = 3 - 4 sec, 25 - 45 sec = 5 - 6 sec, 50 - 75+ sec = 8 -10 sec. They are then told to inhale, hold, exhale, hold (for the duration determined by the C02 discard table) and to repeat this pattern for the entire 5 minutes. If at any point they had to strain to reach these times, they should simply reduce the duration of inhales, exhales, and breath holds. We ask participants to perform all breathing through their nose, if possible.
Study NCT05304000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cyclic Hyperventilation with Retention
Description: Participants are informed they should sit down in a chair or, if they prefer, to lie down, and to set a timer for 5 min. Then they are told to inhale deeply (ideally through their nose but if that is not possible, to inhale through their mouth) and then exhale by passively letting the air fall out from the mouth. We inform them that for sake of this protocol, that pattern of a deep inhale through the nose and passively letting the air fall out from the mouth = 1 breath.~Then they are instructed to perform 30 breaths (in and out) in this manner, and after those 30 breaths, to exhale all their air via their mouth and to calmly wait with lungs empty for 15 seconds.
Study NCT00505895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Arm 1 = 140 mg/m\^2 intravenous over 20 Minutes on Day -1; Arm 2 = 100 mg/m\^2 intravenous over 20 Minutes on Day -1.
Study NCT00505895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 intravenous daily over 30 Minutes for 4 Days (Beginning Day -4).
Study NCT00505895 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Infusion
Description: Stem Cell Infusion on Day 0.
Study NCT00505895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 intravenous on Day -5, +2 +9 and +16.
Study NCT00608452 — intervention group
Intervention type: OTHER
Intervention: Symptom Assessment Scale
Description: * Memorial Symptom Assessment Scale~* History and neurologic examination
Study NCT03517306 — intervention group
Intervention type: OTHER
Intervention: No Interventions
Description: No Interventions
Study NCT01214941 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subjects will be given orally placebo twice a day for 5 days prior to the study.
Study NCT01214941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticlopidine
Description: The subjects will be given orally ticlopidine 250mg twice a day for 5 days prior to the study.
Study NCT01214941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticlopidine and itraconazole
Description: The subjects will be given orally ticlopidine 250mg twice a day and itraconazole 200mg as a single daily dose for 5 days prior to the study.
Study NCT01225978 — intervention group
Intervention type: DEVICE
Intervention: GeneInsight Clinic (GIC)
Description: GeneInsight Clinic (GIC) is a clinical interface tool that provides genetics IT support infrastructure designed to address key genetic data and knowledge management issues.~The GIC enables the delivery of patient specific alerts when new information is learned about a variant after it has been reported to a treating clinician. The prototype for this study shows multiple tests, Hypertrophic Cardiomyopathy test updates, hearing loss test updates and broad spectrum genotyping test updates. Our intention is to build this functionality in a scalable manner that will ultimately accommodate whole genome sequencing.
Study NCT03846219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMU-838 (30 mg/day)
Description: * Main treatment period: All patients will receive half the assigned dose during the first 7 days of the main treatment period (one 15 mg tablet IMU-838 daily) and then start taking the full assigned dose from Day 7 onwards (two 15 mg tablets IMU-838 once daily).~* Optional extended treatment period (optional): Participants who were re-randomized to a 30 mg/day dose will take the full assigned dose which consists of two 15 mg tablets IMU-838 once daily.
Study NCT03846219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMU-838 (45 mg/day)
Description: * Main treatment period: All patients will receive half the assigned dose during the first 7 days of the main treatment period (one 22.5 mg tablet per day) and then start taking the full assigned dose from Day 7 onwards (two 22.5 mg tablets once daily).~* Optional extended treatment period (optional): Participants who were re-randomized to a 45 mg/day dose will take the full assigned dose of two 22.5 mg tablets IMU-838 once daily.
Study NCT03846219 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Main treatment period (Cohort 1 and Cohort 2): All patients will receive 1 tablet per day during the first 7 days of the main treatment period and then start taking 2 tablets once daily from Day 7 onwards.~* Optional extended treatment period: Placebo not applicable as participants were re-randomized to a 30 mg/day dose or a 45 mg/day dose.
Study NCT03846219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMU-838 (10 mg/day)
Description: * Main treatment period for Cohort 2: All patients will receive half the assigned dose during the first 7 days of the main treatment period (one 5 mg tablet per day) and then start taking the full assigned dose from Day 7 onwards (two 5 mg tablets once daily).~* Optional extended treatment period (not applicable to Cohort 2): IMU-838 10 mg/day not applicable.
Study NCT02118857 — intervention group
Intervention type: OTHER
Intervention: Omnivore, vegetarian and vegan subjects.
Description: Omnivore, vegetarian and vegan subjects collected the feces, urina and saliva samples for 3 weeks from recruiting.
Study NCT03812588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram is a Selective Serotonin Reuptake Inhibitor (SSRI) medication that appears to help with symptoms of depression by increasing the availability of specific chemicals in the brain.
Study NCT03812588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo (or dummy pill) is an inert (inactive) substance, typically a tablet, capsule or other dose form that does not contain an active drug ingredient.
Study NCT03954444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxymetazoline Hydrochloride
Description: Test Comparator
Study NCT03954444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rhofade Cream, 1%
Description: Reference Comparator
Study NCT03954444 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study NCT01330563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501, Ketoconazole
Description: Subjects received single 0.5mg doses of CKD-501 alone in one period and, in the other period, Ketoconazole 200 mg twice daily for 5 day with the CKD-501 dose also co-administered with Ketoconazole on day 5.
Study NCT02692456 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Double needle celiac neurolysis (DNCN)
Description: CT guided celiac neurolysis will be performed using 2 needles inserted on each sides of aorta where patient was positioned in prone position
Study NCT02692456 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Single needle celiac neurolysis (SNCN)
Description: CT guided celiac neurolysis will be performed through advancing a single needle to justfront of the aorta near the origin of celiac trunk where patient placed in lateral position
Study NCT03258463 — intervention group
Intervention type: OTHER
Intervention: Change in Texas Law
Description: The change in Texan laws occurring from July 2013-January 2014
Study NCT00671814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701
Description: TR-701 will be given as single oral doses in Cohorts 1-5 and as once daily oral doses for 21 days in cohorts 6-8.
Study NCT00671814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: linezolid
Description: Linezolid will be given at 600 mg twice daily for 21 days in cohort 10.
Study NCT00671814 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo will be given once for cohorts 1-5, once daily for 21 days for cohorts 6-8, and twice daily for 21 days for cohort 10.
Study NCT03721237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EBC-assisted
Description: After definitive catheter positioning, esophageal balloon calibration will be performed in:~1. volume-controlled mode with tidal volume set to obtain 6-8 lm/kg of ideal body weight (reference),~2. pressure support ventilation (PSV) with support set to obtain a tidal volume ranging between 6-8 ml/kg of ideal body weight at equal PEEP of volume control mode (PSV baseline);~3. PSV + sigh ventilation (sigh setting: total inspiratory pressure equal to 35 cmH2O at a rate of 1/ minute; inspiratory time equal to 4 seconds).
Study NCT03283618 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Conferencing Group
Study NCT02700295 — intervention group
Intervention type: DEVICE
Intervention: Orthokeratology lens
Study NCT00305747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR-DIM
Description: 75 mg orally (po) twice daily. May continue treatment for 12 months, however patients will be taken off study if their disease progresses, or have intolerable side effects.
Study NCT03679429 — intervention group
Intervention type: DEVICE
Intervention: NBI Function
Description: In the intervention arm polyps will be optically characterized using the NBI function. The WASP (Workgroup serrAted polypS and Polyposis) classification will be used in order to determine the optical diagnosis.
Study NCT03018457 — intervention group
Intervention type: DEVICE
Intervention: ISQ
Description: Measured by Osstell.
Study NCT00818571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: Mild, moderate and severe renal impaired patients receiving 25 mg vildagliptin once daily
Study NCT00818571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: Mild, moderate and severe renal impaired patients receiving 50 mg vildagliptin once daily
Study NCT00818571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: Matching healthy volunteers receiving 25 mg vildagliptin once daily.
Study NCT00818571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: Matching healthy volunteers receiving 50 mg vildagliptin once daily
Study NCT04176445 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Orthostatic board posture
Description: Patients will be verticalized at at 45º, 60º and 80º using an orthostatic board. The total posture protocol will last 30 minutes
Study NCT04176445 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Bedside sitting posture
Description: Patients will be placed at the bedside, with support for the back and upper limbs. They will be kept at 90º of hip and knee flexion and feet supported. The total posture protocol will last 30 minutes.
Study NCT02034552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg (55 kBq/kg after implementation of NIST \[National Institute of Standards and Technology\] update) every 4 weeks x 6 doses intravenous slow bolus
Study NCT02034552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Abiraterone acetate 1000 mg (4 x 250 mg tablets) taken orally once daily for up to two years following last dose of radium-223 dichloride
Study NCT02034552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 5 mg capsule taken orally twice daily for up to two years following last dose of radium-223 dichloride
Study NCT02034552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide 160 mg (four 40 mg capsules) taken orally once daily for up to two years following last dose of radium-223 dichloride
Study NCT02486367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Standard ADP receptor blockade
Study NCT02486367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: High potency ADP receptor blockade
Study NCT03123055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B-701
Description: B-701 (vofatamab) is a human IgG1 monoclonal antibody that is highly specific for the FGFR3 receptor.
Study NCT03123055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a humanized antibody used in cancer immunotherapy. Pembrolizumab targets and blocks a protein called PD-1 on the surface of certain immune cells called T-cells. Blocking PD-1 triggers the T-cells to find and kill cancer cells.
Study NCT00795353 — intervention group
Intervention type: DRUG
Intervention: Amevive exposure
Description: Commercial alefacept prescribed by Physician
Study NCT04462757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra 100Mg/0.67Ml Inj Syringe
Description: 100 mg interleukin-1 receptor antagonist (r-meth-Hu-IL-1Ra), anakinra; marketed as Kineret® in 0.67 mL prefilled syringe for single use
Study NCT02435641 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: All subjects (patients and caregivers) will complete a battery of psychological questionnaires at baseline (ICU admission), 3 months post-baseline, and 6 months post-baseline.
Study NCT00565058 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GTI-2040
Description: GTI-2040 will be administered one day after HiDAC in the pilot PD study and one day before HiDAC in the Phase II study for a cycle. Those who achieve a complete remission (CR) will be permitted to receive one cycle of consolidation of GTI-2040 and HiDAC
Study NCT04202549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intra-arterial cocktail therapy
Description: Intra-arterial administration of argatroban (0.2-0.3 mg/min), dexamethasone (0.1 mg/min) and edaravone (0.3 mg/min) for 30 to 60 minutes after thrombectomy.
Study NCT00631540 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Formula Balloon-Expandable Stent
Description: renal artery stenting
Study NCT01434264 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Energy healing
Description: Healer-Ringen, a Danish national association of healers, selects healers with an educational background as required by the Registry of Alternative Practitioners (RAB) and have rooms reserved for the healing practice. The treatment takes place in the clinic of the healer and is not restricted in respect to what form of energy healing that shall be used, provided that it is based on the idea of the healer providing some kind of energy by the hands to the participant. Conversation as usual is accepted, but no other form of therapy may be provided. The intervention consists of four sessions over a period of two months, distributed as decided by each participant-healer pair.
Study NCT00736788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1704
Description: single dose oral suspension, 4 different dose levels
Study NCT00736788 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single dose oral suspension
Study NCT01353144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: aspirin, 100 mg, qd x 8 weeks
Study NCT02483689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre Incisional Local Anesthetic
Description: Patient will be given a total of 0.5 mL/kg of 0.25% Bupivicaine either pre-incision: local will be to be given intradermally and onto the peritoneum under direct vision; or post-closure local will be injected intradermally after closure
Study NCT00539240 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rabeprazole 20mg, placebo dinner and bedtime
Description: Breakfast study medication - Rabeprazole 20mg, matching placebo at dinner , Placebo for tricyclic antidepressant at bedtime
Study NCT00539240 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rabeprazole 20 mg two times, Placebo at bedtime
Description: Breakfast \& Dinner study medication - Rabeprazole, placebo for tricyclic antidepressant at bedtime
Study NCT00539240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole 20mg,placebo dinner ,Low dose Tricyclic Antidepressant
Description: Rabeprazole (Breakfast) study medication, dinner placebo medication, tricyclic antidepressant at bedtime
Study NCT02811822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMI-1271
Study NCT02483689 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pre-Incisional Saline
Description: Patient will be given a max of 30 cc injected through a 22g needle to area of incision.
Study NCT02483689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-Closure Local Anesthetic
Description: Patient will be given a total of 0.5 mL/kg of 0.25% Bupivicaine either pre-incision: local will be to be given intradermally and onto the peritoneum under direct vision; or post-closure local will be injected intradermally after closure
Study NCT02483689 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Post-Closure Saline
Description: Patient will be given a max of 30 cc injected through a 22g needle after closing sutures were made.
Study NCT01463436 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: the control group receiving tablet contain calcium carbonate 500 mg/day for 6 months and 12 months
Study NCT01458821 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Fitness Program - Tinnitus
Description: Brain Fitness Program-Tinnitus was developed to improve cognitive function by engaging the brain's neuroplasticity; the program is novel, non-invasive, and inexpensive.
Study NCT02779829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY 987517)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. Formulation number SR15-40-Z12-006.
Study NCT03108209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photoderm Max lait SPF50+
Description: Subjects apply Photoderm Max lait SPF50+ at the beginning of their treatment by Vemurafenib/Cobimetinib in prevention of phototoxicities
Study NCT03108209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photoderm Max Stick SPF50+
Description: Subjects apply Photoderm Max Stick SPF50+ at the beginning of their treatment by Vemurafenib/Cobimetinib in prevention of phototoxicities
Study NCT04072185 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: TThe intervention group will participate in a group physical activity program for 4 months. It will consist of 60 minutes of walking sessions 2 days a week. The sessions will be directed by two referents of each primary care center. Also once a month, coinciding with the walk, you will visit some sociocultural municipal equipment to promote a community connection.
Study NCT01810549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra
Description: Each subject will receive one single subcutaneous injection of 100mg Anakinra during the study, a total of one injection.
Study NCT01810549 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Every subject will receive one single subcutaneous injection of Placebo during the study, a total of one injection.
Study NCT02667379 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diagnostic skin testing
Description: 14 Skin prick tests on each volar forearm with cat dander samples.
Study NCT00131664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avandamet
Description: Avandamet 2 / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily compared to Avandia 4 mg and Amaryl 1 mg once daily over 6 months or compared to Metformin 500 mg twice daily up to 1000 mg over 6 months.
Study NCT00131664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avandia and Amaryl
Description: Avandia 4 mg and Amaryl 1 mg once daily compared to Avandamet 2 / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily, or compared to Metformin 500 mg twice daily up to 1000 mg over 6 months.
Study NCT00131664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 500 mg twice daily up to 1000 mg over 6 months compared to Avandia 4 mg and Amaryl 1 mg once daily or compared to Avandamet 2 / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily
Study NCT00866268 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low pressure suction drainage
Description: In the experimental group the drainage catheter was connected to a modified DRENOFAST® system. This system consisted of a sterile plastic bottle with a holding capacity of 600 mL of fluid and a negative pressure of 700mmHg. It was hermetically closed and had two connections. The DRENOFAST® modification consisted of establishing an open connection between the bottle and a wall vacuum source (normally used to administer oxygen) placed next to the patient's bed. The 50 mmHg constant negative pressure of the bottle was maintained by the wall vacuum source and verified by flow meter. Duration: Drains were removed after bleeding had ceased (48-72h).